Durham, United States
Kincell Bio, founded in 2023, operates as a specialized cell therapy CDMO in the Biopharma, Biotechnology, and Pharmaceutical industries, with headquarters in the United States. Their slogan, Your CDMO Partner from Clinical to Commercial, encapsulates their mission of supporting autologous and allogeneic cell therapies from development through commercial manufacturing.
The company prides itself on being an extension of its clients' teams, emphasizing core principles: Quality First, Better Science, Reliable Supply, Personalized Service, and the Right Scale. With facilities in Gainesville, FL, and Research Triangle Park, NC, Kincell Bio offers a robust array of services including process development, assay optimization, and inspection readiness.
Recently, Kincell Bio secured a $22.00M early VC investment on May 1, 2025, from NewSpring Capital and Kineticos Life Sciences. This funding aims to de-risk development and expedite timelines, ensuring the efficient delivery of tomorrow’s cures with confidence.
